Buy ADT

Logo for stock ADT (ADT)

Amount

£
GBP

Latest price

$8.55
(£1.00 = $1.353)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$7.186B

P/E ratio

14.56

EPS

$0.59

Beta

1.23

Dividend rate

$0.22

Dividend yield

2.56%

About

ADT Inc. is engaged in providing of security, interactive, and smart home solutions serving residential and small business customers in the United States. The Company operates through two segments: Consumer and Small Business (CSB) and Solar. The CSB segment primarily includes the sale, installation, servicing, and monitoring of integrated security and automation systems and other related offerings to owners and renters of residential properties, small business operators, and other individual consumers. The Solar segment primarily includes the sale and installation of solar systems and related solutions and services to residential homeowners. Its security offerings include burglar and life safety alarms, smart security cameras, smart home automation systems, and video surveillance systems. It designs, install, and sell custom residential solar systems and energy storage solutions, energy efficiency upgrades, and roofing services through dedicated and specialized in-house sales.

CEO

Mr. James David (Jim) DeVries

Employees

12,800

Sector

Services

Company HQ

BOCA RATON, United States of America

Website

News

Logo for news article #0 (ASCO 2025: Phase III ARANOTE Post-hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus ADT)

ASCO 2025: Phase III ARANOTE Post-hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus ADT

WHIPPANY, N.J.--(BUSINESS WIRE)--New post-hoc analyses from the investigational Phase III ARANOTE trial showed a clinically meaningful improvement in health-related quality of life (HRQoL) and delayed pain progression for metastatic castration-sensitive prostate cancer (mCSPC) patients treated with NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) versus patients treated with placebo plus ADT.1 The results will be presented at the 2025 American Society of Clinical Oncology (ASCO) A.

Business Wire

May 27, 2025

Logo for news article #1 (Value Grab: Top 10 Stocks Under $10)

Value Grab: Top 10 Stocks Under $10

Tariff turmoil and market downturn are creating buying opportunities for investors looking to capitalize on panic selling and fear. The US-China trade war and rotation from U.S. assets, declining USD, and uncertainty surrounding monetary policy have prompted many investors to de-risk and seek value. Some of the greatest value and growth opportunities can be found in diversifying portfolios with low-priced small-cap stocks - they can offer a bang for your buck.

Seeking Alpha

May 12, 2025

Logo for news article #2 (4 Sizzling Buy-Rated Stocks Trading Under $10 With Massive Upside Potential)

4 Sizzling Buy-Rated Stocks Trading Under $10 With Massive Upside Potential

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

24/7 Wall Street

May 11, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.